InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $1.07B+11.9% | $957.8M+31.8% | $726.4M+40.4% | $517.2M+6.8% | $484.1M |
| Cost of product sales | $89.0M+8.7% | $81.8M+96.6% | $41.6M+309.6% | $10.2M-46.9% | $19.1M |
| Research and development | $328.8M+8.4% | $303.2M-13.8% | $351.6M-2.8% | $361.6M+51.0% | $239.4M |
| Selling, general and administrative | $548.9M+12.4% | $488.4M+20.1% | $406.6M+10.2% | $369.1M-6.8% | $396.0M |
| Gain on sale of non-financial asset | $0+100.0% | -$146.5M | — | — | — |
| Total operating expenses | $966.7M+33.0% | $727.0M-9.1% | $799.8M+8.0% | $740.8M+13.2% | $654.6M |
| Income (loss) from operations | $104.8M-54.6% | $230.8M | — | — | — |
| Interest income, net | $31.7M+24.6% | $25.5M+47.7% | $17.2M+160.7% | $6.6M+1018.4% | $591K |
| Other income | $2.4M+30.1% | $1.8M-64.3% | $5.1M+44.2% | $3.5M+52.1% | $2.3M |
| Income (loss) before income taxes | $138.9M-46.2% | $258.1M | — | — | — |
| Income tax (benefit) expense | -$252.1M-897.2% | $31.6M | — | — | — |
| Consolidated net income | $391.0M+72.7% | $226.5M | — | — | — |
| Earnings (net loss) per share, Basic | $2K+69.3% | $1K | — | — | — |
| Earnings (net loss) per share, diluted | $2K+69.1% | $1K | — | — | — |
| Weighted average common shares outstanding, basic | $168.4M+1.6% | $165.7M+1.2% | $163.8M+1.3% | $161.7M+0.7% | $160.5M |
| Weighted average common shares outstanding, diluted | $169.9M+2.1% | $166.4M+1.6% | $163.8M+1.3% | $161.7M+0.7% | $160.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
ACADIA (ACAD) Upgraded to Buy After Recent Pullback
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release